Kinaxis Maestro selected by Swedish Orphan Biovitrum

Executive Summary

• Swedish Orphan Biovitrum AB (Sobi) has selected Kinaxis Inc.’s Maestro platform to modernize its supply‑chain operations and accelerate delivery of rare‑disease therapies.
• Deloitte Nordics will lead the implementation, providing scenario planning, centralized data management, and attribute‑based planning capabilities across Sobi’s partner network.
• The agreement underscores Kinaxis’ expanding footprint in life‑sciences supply‑chain orchestration and highlights Sobi’s commitment to faster, more reliable access to critical treatments for patients worldwide.

Key Details

• Partnership Scope: Implementation of Kinaxis Maestro platform for end‑to‑end collaboration across Sobi’s global partner network.
• Technology Benefits: Advanced scenario planning, centralized data management, attribute‑based planning, real‑time visibility, and faster response to supply disruptions.
• Implementation Lead: Deloitte Nordics will manage the rollout and integration of Maestro within Sobi’s operations.
• Strategic Rationale (Sobi): Enhance speed, precision, and visibility in the supply chain to support delivery of therapies for rare diseases affecting >40,000 patients annually across 55 countries.
• Strategic Rationale (Kinaxis): Expands Kinaxis’ presence in life‑sciences sector; reinforces its reputation as a leading AI‑infused supply‑chain orchestration provider.
• Executive Comments:
• Norbert Schoellhorn, VP Global Manufacturing & Supply Chain, Sobi – emphasized improved partner connectivity and faster response to change.
• Fabienne Cetre, EVP Europe‑Middle East‑Africa, Kinaxis – highlighted Maestro’s role in unlocking real‑time collaboration for critical therapy delivery.

Notable Quotes

• “Kinaxis is well‑regarded in the life sciences sector for its understanding of the unique complexities of supply chains that define this specific industry,” — Norbert Schoellhorn, Sobi.
• “Sobi will utilize Maestro to unlock real‑time collaboration and seamless execution in order to fast‑track the delivery of critical therapies worldwide,” — Fabienne Cetre, Kinaxis.